Fierce Biotech January 3, 2024
Last summer, GlucoTrack reported preliminary results from a feasibility study of its implantable continuous glucose monitor technology indicating that the sensor could indeed remain safely implanted for at least two years.
Now, a new set of early study results have suggested that in addition to offering a longer-term alternative to standard CGMs, GlucoTrack’s technology also shows promise in improving on its competitors’ accuracy.
The new results come from the implanted CGM’s first preclinical study, which is now complete, according to a company announcement Tuesday.
The study was designed primarily to test the device’s implant technique and overall safety, but also included a small assessment of its accuracy. Among that subset of the sensors put to the test in the study,...
Today's Sponsors
Today's Sponsor